Capricor Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$105MTTM through 30 Jun 2026
Free Cash Flow -$114.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-42.7%ROE
-28.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.35x
Net Debt-$20.9Mnet cash position
Cash & Equivalents$20.9M
Quality Metrics
Altman Z-Score0.93
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$2.45TTMFY2025: $-2.26
Dividend
No dividend
Capital Allocation
R&D Spend$99.7M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.